Genmab

Our headquarter is in Copenhagen, Denmark with sites in Utrecht, the Netherlands, Princeton, New Jersey, U.S. and Tokyo, Japan.

Genmab is a publicly traded, international biotechnology company specializing in the creation and development of differentiated antibody therapeutics for the treatment of cancer.

We are the creators of three marketed products and have a broad clinical and pre-clinical product pipeline. Genmab's technology consists of validated and proprietary next-generation antibody platforms - DuoBody® for generation of bispecific antibodies; HexaBody®, which creates effector-function enhanced antibodies; HexElect®, which combines two co-dependently acting HexaBody molecules to introduce selectivity while maximizing therapeutic potency; and DuoHexaBody®, which enhances the potential potency of bispecific antibodies through hexamerization.

1001+

Scale-up

Untitled_design_9_.png

Untitled_design_10_.png

Untitled_design_11_.png

Publication of the Interim Report for the First Quarter 2022 (after 5:00 PM CEST) - Genmab A/S

(Senior) Clinical Trial Manager - Hybrid

Vice President, Global Digital Strategy & Transformation

Senior Director, Global Medical Affairs Strategy - Solid Tumors

Associate, Facilities Operations

Software Engineering

Data & Analytics

Design

IT & Sysadmin

Sales & Business Development

Marketing & PR & Media

Finance

Legal

HR & Recruitment

Customer Support

(Tech) Project Management

Administration & Office Support

C & Top level Management

Retail

Hospitality & Restaurant

Engineering

Logistics & Supply Chain

Real Estate

Construction

Our core purpose is to improve the lives of patients with cancer by creating and developing innovative and differentiated antibody products. It is our reason for being.

4 jobs at Genmab

4 available offers

Associate, Facilities Operations

Senior Director, Global Medical Affairs Strategy - Solid Tumors

Vice President, Global Digital Strategy & Transformation

(Senior) Clinical Trial Manager - Hybrid

Genmab

The story

1001+

500M+

Offices

Learn more about Genmab

Markets

Follow Us